Sidewinder Therapeutics, a biopharmaceutical company developing novel bispecific antibody-drug conjugates for cancer treatment, has secured $137 million in an oversubscribed Series B funding round. The financing was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from existing investor OrbiMed and new investors like Goldman Sachs Alternatives. This capital infusion will advance Sidewinder's pipeline of innovative cancer therapies.